

Ivan V Pozhidaev

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7773910/publications.pdf>

Version: 2024-02-01

28
papers

227
citations

1039406

9
h-index

1058022

14
g-index

41
all docs

41
docs citations

41
times ranked

238
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene Polymorphisms of Hormonal Regulators of Metabolism in Patients with Schizophrenia with Metabolic Syndrome. <i>Genes</i> , 2022, 13, 844.	1.0	2
2	Genes of the Glutamatergic System and Tardive Dyskinesia in Patients with Schizophrenia. <i>Diagnostics</i> , 2022, 12, 1521.	1.3	1
3	Genetic Polymorphisms of 5-HT Receptors and Antipsychotic-Induced Metabolic Dysfunction in Patients with Schizophrenia. <i>Journal of Personalized Medicine</i> , 2021, 11, 181.	1.1	11
4	Preliminary Pharmacogenetic Study to Explore Putative Dopaminergic Mechanisms of Antidepressant Action. <i>Journal of Personalized Medicine</i> , 2021, 11, 731.	1.1	4
5	Comparative Characteristics of the Metabolic Syndrome Prevalence in Patients With Schizophrenia in Three Western Siberia Psychiatric Hospitals. <i>Frontiers in Psychiatry</i> , 2021, 12, 661174.	1.3	7
6	Search for Possible Associations of FTO Gene Polymorphic Variants with Metabolic Syndrome, Obesity and Body Mass Index in Schizophrenia Patients. <i>Pharmacogenomics and Personalized Medicine</i> , 2021, Volume 14, 1123-1131.	0.4	7
7	Influence of eight ABCB1 polymorphisms on antidepressant response in a prospective cohort of treatment-free Russian patients with moderate or severe depression: An explorative psychopharmacological study with naturalistic design. <i>Human Psychopharmacology</i> , 2021, , e2826.	0.7	5
8	Pharmacogenetics of tardive dyskinesia in schizophrenia: The role of <i>CHRM1</i> and <i>CHRM2</i> muscarinic receptors. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 72-77.	1.3	13
9	Therapeutic Drug Monitoring of Olanzapine and Cytochrome P450 Genotyping in Nonsmoking Subjects. <i>Therapeutic Drug Monitoring</i> , 2020, 42, 325-329.	1.0	6
10	P.583 Polymorphisms in BDNF, AKT1, GSK3B genes: possible association with antipsychotic-induced hyperprolactinemia in schizophrenia patients. <i>European Neuropsychopharmacology</i> , 2020, 40, S331-S332.	0.3	0
11	NRG1, PIP4K2A, and HTR2C as Potential Candidate Biomarker Genes for Several Clinical Subphenotypes of Depression and Bipolar Disorder. <i>Frontiers in Genetics</i> , 2020, 11, 936.	1.1	13
12	COMT gene polymorphism and antipsychotic-induced hyperprolactinemia in schizophrenia patients. , 2020, , .		0
13	5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia. <i>Frontiers in Molecular Neuroscience</i> , 2020, 13, 63.	1.4	9
14	<p></p>Association of Cholinergic Muscarinic M4 Receptor Gene Polymorphism with Schizophrenia</p>. <i>The Application of Clinical Genetics</i> , 2020, Volume 13, 97-105.	1.4	7
15	Association of ANKK1 polymorphism with antipsychotic-induced hyperprolactinemia. <i>Human Psychopharmacology</i> , 2020, 35, e2737.	0.7	4
16	Association between 8 P-glycoprotein (MDR1/ABCB1) gene polymorphisms and antipsychotic drug-induced hyperprolactinaemia. <i>British Journal of Clinical Pharmacology</i> , 2020, 86, 1827-1835.	1.1	13
17	A pharmacogenetic study of patients with schizophrenia from West Siberia gets insight into dopaminergic mechanisms of antipsychotic-induced hyperprolactinemia. <i>BMC Medical Genetics</i> , 2019, 20, 47.	2.1	17
18	Tardive dyskinesia in schizophrenia: Gene polymorphisms of muscarinic and adrenergic receptors. <i>European Neuropsychopharmacology</i> , 2019, 29, S117-S118.	0.3	0

#	ARTICLE	IF	CITATIONS
19	The study of dopamine receptor genes in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2019, 29, S410-S411.	0.3	0
20	Limited Associations Between 5-HT Receptor Gene Polymorphisms and Treatment Response in Antidepressant Treatment-Free Patients With Depression. <i>Frontiers in Pharmacology</i> , 2019, 10, 1462.	1.6	15
21	No evidence so far of a major role of <i>AKT1</i> and <i>GSK3B</i> in the pathogenesis of antipsychotic-induced tardive dyskinesia. <i>Human Psychopharmacology</i> , 2019, 34, e2685.	0.7	5
22	Polymorphisms of Catechol-O-Methyl Transferase (COMT) Gene in Vulnerability to Levodopa-Induced Dyskinesia. <i>Journal of Pharmacy and Pharmaceutical Sciences</i> , 2018, 21, 340-346.	0.9	10
23	Association Between Prolactin Gene Polymorphism (1149 G/T) and Hyperprolactinemia in Anti-psychotic Treated Patients with Schizophrenia. <i>European Psychiatry</i> , 2017, 41, S267-S267.	0.1	0
24	Prolactin gene polymorphism (1149 G/T) is associated with hyperprolactinemia in patients with schizophrenia treated with antipsychotics. <i>Schizophrenia Research</i> , 2017, 182, 110-114.	1.1	24
25	Identification of 5-hydroxytryptamine receptor gene polymorphisms modulating hyperprolactinaemia in antipsychotic drug-treated patients with schizophrenia. <i>World Journal of Biological Psychiatry</i> , 2017, 18, 239-246.	1.3	28
26	Association of polymorphism in the dopamine receptors and transporter genes with hyperprolactinemia in patients with schizophrenia. <i>European Neuropsychopharmacology</i> , 2017, 27, S923-S924.	0.3	0
27	Association of <i>DRD4</i> gene polymorphisms with Parkinson's disease. <i>Bulletin of Siberian Medicine</i> , 2017, 16, 70-78.	0.1	0
28	CYP1A2 and CYP2D6 Gene Polymorphisms in Schizophrenic Patients with Neuroleptic Drug-Induced Side Effects. <i>Bulletin of Experimental Biology and Medicine</i> , 2016, 160, 687-690.	0.3	25